多参数Z谱MRI在临床患者中对胶质瘤分层可能具有良好的性能
该回顾性研究纳入113例胶质瘤患者,用多对比度Z谱MRI拟合五种对比度,评估其在肿瘤分级、IDH基因型和1p/19q共缺失状态分层中的性能。结果显示DSW在分级、IDH基因型和1p/19q状态间均有显著差异,联合所有Z谱对比度可提高各风险分层的敏感度和特异度。
要点
- DSW在肿瘤分级、IDH基因型和1p/19q共缺失状态间均存在显著差异。
- APT在分级和IDH突变间有显著差异,但与1p/19q亚型无关。
- CEST@2ppm仅与1p/19q共缺失亚型显著相关。
核心结论
- 多参数Z谱MRI可作为临床患者胶质瘤分层的有用、全面且无创的影像技术。
研究设计与样本
- 回顾性纳入113例胶质瘤患者,采用多对比度Z谱MRI,用五个独立洛伦兹函数拟合DSW、MTC、APT、脂肪族NOE和CEST@2ppm,以肿瘤分级、IDH基因型和1p/19q共缺失状态为参考标准进行分层比较。
诊断标准与关键数值
- DSW在肿瘤分级、IDH基因型和1p/19q共缺失状态间均存在显著差异。
- APT在肿瘤分级和IDH突变间存在显著差异,但与1p/19q亚型无显著差异。
- CEST@2ppm仅与1p/19q共缺失亚型存在显著差异。
- 在IDH突变胶质瘤中,DSW和CEST@2ppm可区分1p/19q共缺失亚型。
- ROC分析中,区分肿瘤分级时DSW的AUC最大;区分IDH基因型时DSW和APT的AUC相当;区分1p/19q共缺失状态时DSW在所有患者和IDH突变患者中均为最佳指标。
临床应用与阅片要点
- 多参数Z谱MRI可无创评估胶质瘤分级、IDH基因型和1p/19q共缺失状态。
- 联合所有Z谱对比度可提高所有风险分层的敏感度和特异度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To comprehensively and noninvasively risk-stratify glioma grade, isocitrate dehydrogenase (IDH) genotype, and 1p/19q codeletion status using multi-contrast Z-spectral magnetic resonance imaging (MRI).
METHODS: One hundred and thirteen patients with glioma were retrospectively included. Multiple contrasts contributing to Z-spectra, including direct saturation of water (DSW), semi-solid magnetization transfer contrast (MTC), amide proton transfer (APT) effect, aliphatic nuclear Overhauser effect, and the 2-ppm chemical exchange saturation transfer peak (CEST@2ppm), were fitted with five individual Lorentzian functions. Z-spectral contrasts were compared according to the three most important risk stratifications: tumor grade, IDH genotype, and 1p/19q codeletion status. We further investigated the differentiation of 1p/19q codeletion status within IDH mutant gliomas. The stratification performance of individual Z-spectral contrasts and their combination was quantified using receiver operating characteristic (ROC) analyses.
RESULTS: DSW was significantly different within grade, IDH genotypes, and 1p/19q codeletion status. APT was significantly different with grade and IDH mutation, but not with 1p/19q subtypes. CEST@2ppm was only significantly different with 1p/19q codeletion subtypes. DSW and CEST@2ppm were the two Z-spectral contrasts able to differentiate 1p/19q codeletion subtypes within IDH mutant gliomas. For differentiating glioma grades using ROC analyses, DSW achieved the largest AUC. For differentiating IDH genotypes, DSW and APT achieved comparable AUCs. DSW was the best metric for differentiating 1p/19q codeletion status within all patients and within the IDH mutant patients. Combining all Z-spectral contrasts improved sensitivity and specificity for all risk stratifications.
CONCLUSIONS: Multi-parametric Z-spectral MRI serves as a useful, comprehensive, and noninvasive imaging technique for glioma stratification in clinical patients.
KEY POINTS: • Multiple contrasts contributing to Z-spectra were separately fitted with Lorentzian functions. • Z-spectral contrasts were compared within the three most important and common tumor risk stratifications for gliomas: tumor grade, IDH genotype, and 1p/19q codeletion status. • The stratification performance of individual Z-spectral contrasts and their combination was quantified using receiver operating characteristic analyses, which found Z-spectral MRI to be a useful and comprehensive imaging biomarker for glioma stratification.
引用
- Su C, Xu S, Lin D, et al. Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients. Eur Radiol. 2021. PMID: 34272981. doi:10.1007/s00330-021-08175-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。